Undervalued Dividend Stocks – April 2026
Mastercard is an inflation hedge trading at its lowest forward valuation in over 5 years
Mastercard's fee-based model (percentage of transaction value) makes it a natural inflation hedge. Despite 83% gross margin, 48% ROIC, and a projected 16.33% EPS CAGR over 3-5 years, it trades at its lowest forward P/E in over 5 years with no fundamental deterioration — creating a historically attractive entry point.
| Instrument | Side | Target | Reason |
|---|---|---|---|
| MA | Long | Lowest forward P/E in 5+ years despite 16.33% projected EPS CAGR; inflation automatically lifts revenue through transaction-value-based fees; structural tailwinds from digital payments, cross-border volumes, and high-margin Value-Added Services (fraud, data analytics, cybersecurity). |
Williams Companies sits at the intersection of AI power demand, LNG export growth, and inflation-indexed revenues
WMB's Transco pipeline is structurally irreplaceable with 95% fee-based cash flows. Three converging catalysts — a $5.1B AI-linked Power Innovation segment (10-year take-or-pay with Meta), U.S. LNG export capacity doubling by 2028, and FERC-regulated revenues indexed to PPI — support a sensitivity-based price target of $99/share on a 2-year 10% EBITDA CAGR, despite WMB trading at a lower multiple than peers while growing faster with higher margins and lower leverage.
| Instrument | Side | Target | Reason |
|---|---|---|---|
| WMB | Long | $99 | 95% fee-based cash flows insulated from commodity prices; $5.1B Power Innovation segment with 10-year take-or-pay contracts (Meta, hyperscalers); LNG export capacity doubling by 2028 drives incremental Transco throughput; PPI-indexed FERC revenues translate inflation directly to EBITDA; lower valuation multiple than KMI despite faster EBITDA growth, higher margins, and lower leverage. |
AbbVie's post-Humira transformation is underappreciated and the stock offers a compelling setup for a Dividend King
AbbVie replaced Humira revenues ahead of schedule — Skyrizi and Rinvoq delivered $25.9B in 2025, surpassing the company's own 2027 guidance two years early. Management guides >$31B combined in 2026 (+20% YoY). The stock is down ~15% from October highs on competitive (J&J oral psoriasis approval) and legal (340B discount expansion) fears, yet all major growth targets are on track or raised. At a forward P/E of ~14.2x with a 3.22% yield and high-single-digit revenue CAGR through 2029, analyst consensus targets $255.
| Instrument | Side | Target | Reason |
|---|---|---|---|
| ABBV | Long | $255 | Skyrizi and Rinvoq exceeded 2027 guidance by $500M two years early; 2026 combined guidance >$31B (+20% YoY); 2026 adjusted EPS guided at $14.37-$14.57 (45%+ reset as Humira drag fades); forward P/E ~14.2x for a Dividend King; 3.22% yield with 5-year dividend CAGR of 5.9% and 54 consecutive years of increases; high-single-digit revenue CAGR guided through 2029. |
Themes
The content on this page is for informational purposes only and does not constitute financial advice. Stoquate is not a licensed financial advisor. Always conduct your own research and consult a qualified professional before making any investment decisions.